|
The
following potentially dilutive securities were excluded from the calculation of diluted net loss per share because their effect would
have been antidilutive:
Schedule of Anti-dilutive Securities
| |
|
2026 |
|
|
2025 |
|
| |
|
Three
Months Ended
March
31,
|
|
| |
|
2026 |
|
|
2025 |
|
| Stock
options |
|
|
1,076,312 |
|
|
|
25,663 |
|
| Warrants |
|
|
17,687 |
|
|
|
24,552 |
|
| Common shares issuable upon conversion of Series F Preferred Stock |
|
|
249,624 |
|
|
|
- |
|
| Common shares issuable upon conversion of warrants attached to Series H Preferred Stock |
|
|
23,925,000 |
|
|
|
- |
|
| Common
shares issuable upon conversion of Series H Preferred Stock |
|
|
15,525,549 |
|
|
|
- |
|
| Total |
|
|
40,794,172 |
|
|
|
50,215 |
|
|